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Abstract
Background: Dysfunctions in autophagy and apoptosis are closely interacted and play an important role in cancer
development. RNA binding motif 5 (RBM5) is a tumor suppressor gene, which inhibits tumor cells’ growth and
enhances chemosensitivity through inducing apoptosis in our previous studies. In this study, we investigated the
relationship between RBM5 overexpression and autophagy in human lung adenocarcinoma cells.
Methods: Human lung adenocarcinoma cancer (A549) cells were cultured in vitro and were transiently transfected
with a RBM5 expressing plasmid (GV287-RBM5) or plasmid with scrambled control sequence. RBM5 expression was
determined by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot.
Intracellular LC-3 I/II, Beclin-1, lysosome associated membrane protein-1 (LAMP1), Bcl-2, and NF-κB/p65 protein
levels were detected by Western blot. Chemical staining with monodansylcadaverine (MDC) and acridine orange
(AO) was applied to detect acidic vesicular organelles (AVOs). The ultrastructure changes were observed under
transmission electron microscope (TEM). Then, transplanted tumor models of A549 cells on BALB/c nude mice were
established and treated with the recombinant plasmids carried by attenuated Salmonella to induce RBM5
overexpression in tumor tissues. RBM5, LC-3, LAMP1, and Beclin1 expression was determined by
immunohistochemistry staining in plasmids-treated A549 xenografts.
Results: Our study demonstrated that overexpression of RBM5 caused an increase in the autophagy-related
proteins including LC3-I, LC3-II, LC3-II/LC3-I ratio, Beclin1, and LAMP1 in A549 cells. A large number of
autophagosomes with double-membrane structure and AVOs were detected in the cytoplasm of A549 cells
transfected with GV287-RBM5 at 24 h. We observed that the protein level of NF-κB/P65 was increased and the
protein level of Bcl-2 decreased by RBM5 overexpression. Furthermore, treatment with an autophagy inhibitor,
3-MA, enhanced RBM5-induced cell death and chemosensitivity in A549 cells. Furthermore, we successfully
established the lung adenocarcinoma animal model using A549 cells. Overexpression of RBM5 enhanced the
LC-3, LAMP1, and Beclin1 expression in the A549 xenografts.
Conclusions: Our findings showed for the first time that RBM5 overexpression induced autophagy in human lung
adenocarcinoma cells, which might be driven by upregulation of Beclin1, NF-κB/P65, and downregulation of Bcl-2.
RBM5-enhanced autophagy acts in a cytoprotective way and inhibition of autophagy may improve the anti-tumor
efficacy of RBM5 in lung cancer.
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Background
Lung cancer is the leading cause of cancer-related mor-
tality in the world [1]. Nearly 85 % of these are non-
small cell lung cancer (NSCLC), which typically has a
poor prognosis with the overall 5-year survival rate of
~17 % despite innovations in diagnostic testing, surgical
technique, and development of new chemotherapeutic
agents [1, 2]. Thus, studies on new therapeutic strategies
or targets are of great interest. Several of these studies
are designed to target RBM5, since deregulation of
RBM5 and its downstream targets have been linked to
tumorigenesis and tumor maintenance in a variety of
cancers, including lung cancer, breast cancer, pancreatic
cancer, prostate cancer, and vestibular schwannoma [3–8].
RNA binding motif 5 (RBM5) (also called Luca15 or
H37), the tumor suppressor gene, maps to the human
chromosomal locus 3p21.3, which is strongly associated
with lung cancer [9]. It has been shown to function as a
regulator of apoptosis and cell cycle arrest in several ma-
lignancies, particularly in NSCLC cells through pre-
messenger RNA (mRNA) splicing of multiple target genes
[10–12]. The ectopic expression of RBM5 suppresses the
growth of human lung cancer [11], breast cancer [13],
fibrosarcoma [14], and hematopoietic cells [15–17]. Our
previous study demonstrated that exogenous expression
of RBM5 by the pcDNA3.1-RBM5 inhibited the cell
growth of human prostate cancer and lung cancer in vivo
and in vitro and resensitized the response of A549/DDP
cells (cisplatin resistant counterparts of A549 cells) to
cisplatin [8, 18–20]. Although the mechanisms of RBM5-
mediated tumor suppression remain not quite clear,
recent studies suggest that RBM5 is involved in the regu-
lation of the mitochondrial apoptotic pathway and Bcl-2
family expression [8, 18, 19]. It has been confirmed that
Bcl-2 family also function as autophagy regulators via their
interaction with the core autophagy factor Beclin family
which plays an important role in the initiation of autopha-
gosome formation [21–24]. However, the relationship be-
tween RBM5 and autophagy in human lung cancer is still
unknown.
Autophagy is an evolutionarily conserved process in all
eukaryotic cells, which is used for recycling cytoplasm to
generate macromolecular building blocks and energy
under stress conditions, to remove superfluous and dam-
aged proteins and organelles to adapt to changing nutrient
conditions and to maintain cellular homeostasis [25, 26].
Autophagy has been recognized as having a complex im-
pact on the initiation, progression, and treatment of lung
cancer [27]. Low expression of Beclin1 was significantly
associated with tumorigenesis, tumor progression, and
poor prognosis in NSCLC [28]. Inactivation of the essen-
tial autophagy gene Atg5 causes an acceleration of the
early phases of NSCLC oncogenesis [29]. Suppression
of basal autophagy leads to inhibition of NSCLC cell
proliferation and sensitizes them to cisplatin-induced
caspase-dependent and caspase-independent apoptosis
[30]. The initiation and execution of autophagy is regu-
lated by a number of intracellular molecules, such as
autophagy-related (Atg) proteins, mTORC1, AMPK,
Beclin1, Bcl-2, and PI3K/AKT pathway [27]. Although the
understanding of the regulation of autophagy has substan-
tially advanced, information on the regulation of this com-
plex process is limited.
In this study, we investigated the relationship of RBM5
overexpression and its potential role of autophagy modula-
tion, which will help us to learn more about the mechanism
of potential activity of RBM5 and autophagy regulation in
NSCLC. Our data showed for the first time that RBM5
overexpression induced autophagy, which might be regu-
lated by the alteration of NF-κB/P65 and Bcl-2 expression.
Methods
Cell lines and expression vectors
The human lung adenocarcinoma cell line A549 cells
were obtained from the Chinese Academy of Medical
Sciences. A549 cells were cultured in RPMI-1640
medium (Gibco, USA), supplemented with 10 % fetal
bovine serum (Gibco, USA), 100 U/mL penicillin, and
100 μg/mL streptomycin (Sigma-Aldrich, St. Louis,
USA) at 37 °C and 5 % CO2 with high humidity.
Expression vectors and reagents
RBM5 expression plasmid (NM_005778) (GV287-RBM5)
and the plasmid with scrambled control sequence (GV287)
were constructed by Genechem Company (Genechem,
China). Cisplatin were purchased from Sigma Chemical Co.
(Sigma Chemical Co., St. Louis, USA).
Transient transfections and treatments
A549 cells were transiently transfected with recombined
plasmid with RBM5 gene (GV287-RBM5) or plasmid
with scrambled control sequence using Lipofectamine
2000 reagent (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instruction as described previously
[19, 20, 31], with 4 μg DNA for 9 × 105 A549 cells in a
six-well plate. Five hours after the transfection, the cell
culture medium was replaced with 10 % fetal bovine
serum. For the pharmacological modulation of autoph-
agy, cells were treated with 3-MA (5 mM), which is a
class III phosphatidylinositol 3-kinase (PtdIns3K) inhibi-
tor and can block the early steps of autophagy [32] at
the same time. Twenty-four hours after transfection, the
cells were stained, or harvested, or treated with cisplatin
for another 24 h for MTT assays.
Cell viability assays
Cell viability was determined using 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays.
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Cells were seeded at 2 × 104 cells in 100 μl per well in
96-well plates for 12 h. Then, cells were treated with dif-
ferent concentrations of cisplatin for 24 h. The cells
were treated with 0.5 mg/ml MTT solution and incu-
bated for 4 h at 37 °C in the dark. The supernatant was
aspirated, and formazan crystals were dissolved in 100 μl
of DMSO at 37 °C for 15 min with gentle agitation. The
absorbance value at a wavelength of 570 nm was mea-
sured with a microplate reader (Bio-Rad, Richmond,
CA). Cell viability was calculated as a percentage of the
control (untreated) values. All experiments were carried
out in triplicate.
Acridine orange staining
Acridine orange (AO) (Sigma Chemical Co., St. Louis,
USA) was used to evaluate the formation of acid vesicular
organelles (AVOs) by fluorescence microscopy. AO is a
fluorescent molecule used to identify either apoptotic cell
death or autophagy. It can interact with DNA emitting
green fluorescence or accumulate in acidic organelles in
which it becomes protonated forming aggregates that emit
bright red fluorescence. After transfected with plasmids
for 24 h, cells were treated with AO (1 μg/ml) in a serum-
free medium and incubated for 15 min at 37 °C in the
dark. Then, cells were washed four times with PBS, and
fluorescent micrographs were obtained using an inverted
fluorescence microscope (Olympus, Japan).
MDC incorporation assay
Another fluorescent compound, monodansylcadaverine
(MDC) has been proposed as a tracer for autophagic vac-
uoles. Autophagic vacuoles were also detected with MDC
staining. After transfected with plasmids for 24 h, cells
were incubated with MDC (50 μM) (Sigma Chemical Co.,
St. Louis, USA) in a serum-free medium at 37 °C for
30 min in the dark. After incubation, cells were washed
four times with cold PBS, and fluorescent micrographs
were obtained using an inverted fluorescence microscope
(Olympus, Japan).
Transmission electron microscopy
Treated cells were washed and fixed in 2.5 % glutaralde-
hyde for 2 h at 4 °C and then treated with 1 % osmium
tetroxide, dehydrated in a graded series of ethanol baths,
infiltrated and embedded in Epon resin. Ultrathin sec-
tions of 70 nM were cut in a Leica microtome (Leica,
Deerfield, III), poststained with uranyl acetate and lead
citrate, and examined in a HITACHI H-7650 transmis-
sion electron microscope (TEM) (HITACHI, Ltd, Japan)
at an accelerating voltage of 80 kV.
Protein extraction and Western blot
Total protein from cultured cells was extracted according
to the previous study [31]. Briefly, protein concentration
was measured by the Protein Assay Kit (Bio-Rad, CA).
Equal amounts of protein samples (20–50 μg) were sep-
arated by 12 % SDS-PAGE and transferred onto poly
(vinyl idene fluoride) (PVDF) membranes (Millipore,
USA). The membranes were treated with Tris-buffered
saline and Tween-20 solution (TBST) containing 50 g/L
skim milk at room temperature for 1 h, and incubated
overnight at 4 °C with an antibody against RBM5 (Santa
Cruz Biotechnology, CA), LC3A/B (Proteintech Group,
USA), Beclin1 (Proteintech Group, USA), Bcl-2 (Protein-
tech Group, USA), NF-κB/p65 (Affinity, USA), or LAMP1
(Abcam, USA). The mouse monoclonal antibody against
β-actin (Proteintech Group, USA) was used as a house-
keeping control gene. Membranes were washed three
times for 10 min with TBST and incubated with horserad-
ish peroxidase-conjugated secondary antibodies (Protein-
tech Group, USA) at a dilution of 1:500 for 1 h at room
temperature. Membranes were washed three times for
10 min with TBST, and bands were then detected using an
Enhanced Chemiluminescence (ECL) Detection kit (Pierce
Biotechnology Ltd., Rockford, IL, USA) and quantified by
densitometry using Quantity One software (Bio-Rad).
RNA extraction and semi-quantitative RT-PCR
Reverse transcription-polymerase chain reaction (RT-
PCR) was performed essentially as described previously
[20]. In brief, total RNA was extracted from the cells
using a Trizol reagent (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s protocol. The ratio of absorb-
ance at 260 and 280 nm (A260/280) was measured to
assess RNA purity and quantity. First-strand comple-
mentary DNA (cDNA) was generated using All-in-One™
First-Strand cDNA Synthesis Kit (GeneCopoeia, Inc,
USA) according to the manufacturer’s instructions.
Primers were made by Sangon Biotech (Sangon Biotech,
China). The primer sequences were as follows: GAPDH
sense: 5′-CATGTAGTTGAGGTCAATGAAGG-3′ and
antisense: 5′-GAGCCACATCGCTCAGACAC-3′; RBM5
sense: 5′-GCACGACTATAGGCATGACAT-3′ and anti-
sense: 5′-AGTCAAACTTGTCTGCTCCA-3′. PCR was
performed at 95 °C for 5 min and 28–30 cycles of 95 °C
for 30 s, 58 °C for 30 s, 72 °C for 45 s, and 72 °C for
10 min. The PCR products were separated by electrophor-
esis on 1 % agarose gels containing ethidium bromide.
The PCR products were visualized by a Tanon-1600 figure
gel image processing system and analyzed with a GIS 1D
gel image system software (Tanon, Shanghai, China).
Establishment of A549 xenografts
The use of animal was in accordance with animal care
guidelines, and the protocol was approved by Jilin
University Animal Care Committee. A549 xenografts
were established, and RBM5 gene was delivered into xeno-
grafts by attenuated Salmonella according to previous
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studies [18, 31]. Briefly, BALB/c athymic nude female
mice (nu/nu; 4–5 weeks old) were purchased from the In-
stitute of Zoology, Chinese Academy of Sciences (Beijing,
China). A549 cells (1 × 107) were suspended in 100 μl PBS
and injected subcutaneously into the right flank region of
nude mice.
Competent Salmonella enterica serovar Typhimur-
ium cells (competence) were mixed with 1 μg GV287-
RBM5 or 1 μg control plasmids and cooled for 15 min on
ice. And the plasmids were electrotransfected into the
competence under the conditions as follows: C = 25 μF,
PC = 200 Ω, V = 1.25 kV (12.5 kV/cm). Then, the recom-
binant attenuated salmonellae were quickly transferred
into LB Ager medium for proliferation at 37 °C and stored
at −80 °C.
The tumor-bearing mice were randomly divided into
two groups (six mice per group) at day 21 after cell injec-
tion. The mice were treated at day 28 and 35 respectively
through a tail mainline as follows: (a) control group (at-
tenuated Salmonella carrying control plasmids) (108
colony-forming units (CFU) per 50μlPBS); (b) RBM5 over-
expression group (attenuated salmonella carrying GV287-
RBM5 plasmids) (108 CFU per 50 μl PBS). The mice were
sacrificed on day 42, and the tumors were removed and
fixed in formalin for immunohistochemistry analysis.
Immunohistochemistry staining
Tumors treated with recombinant Salmonella strains
carrying different plasmids were analyzed by immuno-
histochemistry staining as described previously [18].
Anti-human mouse RBM5 antibody was obtained from
Santa Cruz Biotechnology (Santa Cruz Biotechnology,
USA). Anti-human rabbit LC-3 antibody was obtained
from Proteintech Group (Proteintech Group, USA).
Anti-human rabbit LAMP1 antibody was obtained from
Abcam (Abcam, USA). Anti-human rabbit Beclin1 anti-
body was obtained from Proteintech Group (Proteintech
Group, USA).
Statistical analysis
All data were presented as mean ± standard deviation (SD)
for three independent experiments. Student’s t test was
used to compare the difference between two groups (two-
tailed; P < 0.05 was considered statistically significant). The
analysis was performed using SPSS 17.0 software.
Results
Ectopic expression of RBM5 enhanced autophagic
vacuoles formation in A549 cells
We previously reported that RBM5 overexpression in-
duced apoptosis in human lung adenocarcinoma A549
cells [19, 20]. However, the relationship between RBM5
overexpression and autophagy, which is closely related to
apoptosis, has not been elucidated. To investigate whether
ectopic expression of RBM5 modulates autophagy ma-
chinery in A549 cells, A549 cells were transiently trans-
fected with RBM5 expressing plasmid (GV287-RBM5)
(RBM5 group) or negative control plasmid (control
group).
We firstly examined expression level of RBM5 by RT-
PCR and Western blot analysis. The mRNA and protein
expression levels of RBM5 were significantly increased
in the RBM5 transfected cells (P < 0.05, P < 0.001, re-
spectively) (Fig. 1a–d), indicating that GV287-RBM5 was
successfully transfected into A549 cells.
AO and MDC are fluorescent substances, which are
specific markers for autophagic vacuoles and are often
used to detect the occurrence of autophagy [33]. In AO
stained cells, cytoplasm and nucleolus showed green
fluorescence whereas AVOs showed bright red fluores-
cence. Intensity of red fluorescence is proportional to
the number of AVOs in autophagic cells. With AO
staining, we observed that red fluorescent spots were in-
creased in RBM5 overexpressed A549 cells compared to
the control cells (Fig. 1e), indicating that RBM5 overex-
pression enhanced autophagic vacuoles formation.
When cells were co-treated with RBM5 transfection and
a classic autophagy inhibitor 3-MA (5 mM), the incre-
ment of acridine orange-positive AVOs was inhibited
and there were more nucleus presenting yellow-green
fluorescence by acridine orange (AO) staining and con-
centrating into a crescent or granules that located in one
side of the cells compared to RBM5 group (Fig. 1e), sug-
gesting that 3-MA inhibited RBM5 induced autophagy
and enhanced RBM5 induced early-stage apoptosis.
MDC accumulates in mature autophagic vacuoles, such
as autophagolysosomes, but not in the early endosome
compartment [34]. In MDC stained cells, AVOs appear
as distinct dot-like structures distributed within the
cytoplasm or localizing in the perinuclear regions. With
MDC staining, we observed that the RBM5 overex-
pressed A549 cells showed a greater fluorescence inten-
sity and a greater number of MDC-labeled particles in
the cytoplasm of the cells compared to the control
group (Fig. 1f ), indicating that overexpression of RBM5
increased MDC recruitment to autophagosomes which
was suppressed by the autophagy inhibitor, 3-MA
(Fig. 1f ).
Additionally, ultrastructural changes in treated cells
were examined with TEM. TEM images in control group
displayed normal cytoplasm and were characterized by
mitochondria, endoplasmic reticulum, free ribosomes, and
irregular nucleus, as well as few autophagosomes and ly-
sosomes (Fig. 1g). In contrast, RBM5 group exhibited
many autophagosomes at various stages in cytoplasm. Ar-
rows indicated typical double-membrane-bound vacuoles
containing morphologically intact cytoplasm, organelles,
or electron-dense contents (Fig. 1g). The co-treated A549
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Fig. 1 Overexpression of RBM5 enhanced autophagic vacuoles formation in A549 cells. A549 cells were transfected with recombined GV287-RBM5
plasmids (RBM5 group), plasmids with scrambled control sequence (control group), or co-treated with RBM5 transfection and classic autophagy inhibitor
3-MA (RBM5 + 3-MA group). a RT-PCR analysis of the mRNA levels of RBM5 and GAPDH in A549 cells. b Quantification of RBM5 mRNA levels relative to
GAPDH. c Western blot analysis of the protein expression levels of RBM5 and β-actin in A549 cells. d Quantification of RBM5 protein expression relative to
β-actin. e Images of acridine orange (AO) staining under fluorescence microscope. f Images of Monodansylcadaverine (MDC) staining.
g Images acquired by transmission electron microscope. Data were presented as mean ± SD for three replicate experiments. *P < 0.05, ***P < 0.001
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cells exhibited less autophagosomes than RBM5 group but
showed the following findings: peripheral chromatin con-
densation, undulations in the boundaries of the nucleus,
lipid droplets, glycogen accumulation, mitochondrial in-
jury, degeneration and dilatation of the endoplasmic
reticulum, increased lysosomes, and intracytoplasmic
vacuolization (Fig. 1g), indicating that 3-MA inhibited
RBM5-induced autophagy but enhanced RBM5-induced
apoptosis.
Overexpression of RBM5 induced cell autophagy-related
protein expression
To estimate whether double-membrane-bound vacuoles
accumulation, which was observed in the fluorescent
staining and TEM analysis, was due to an increase in the
autophagic flux, we analyzed the expression levels of
autophagosomal (LC3-I and LC3-II) and lysosomal
(LAMP1) markers by Western blot analysis at 24 h fol-
lowing transfection. During autophagy, LC3-I undergoes
cleavage and lipidation to yield LC3-II, which is a reli-
able protein marker associated with completed autopha-
gosomes. The amount of LC3-II and the ratio of LC3-II/
LC3-I might be correlated to the numbers of autophagic
vesicles in the cell. The LC3-I and LC3-II expression
levels (Fig. 2a, b; P < 0.05 and P < 0.01, respectively) and
the ratio of LC3-II/LC3-I (Fig. 2c; P < 0.001) in the
RBM5 group were significantly increased compared to
the control group, indicating that overexpression of
RBM5 induces autophagosomes formation. But the
administration of 3-MA significantly decreased the ex-
pression levels of LC3-I, LC3-II (Fig. 2a, b; P < 0.05) and
the ratio of LC3-II/LC3-I (Fig. 2c; P < 0.001) in the co-
treatment group compared to those in the RBM5 group.
LAMP1 is a structural protein on the membranes of late
endosomes and lysosomes and is well-known for its regu-
lation of lysosomal motility and membrane fusion events
between autophagosomes with late endosomes/lysosomes
[35]. We observed that LAMP1 expression was increased
significantly in RBM5 overexpressed A549 cells compared
to that in the control group (Fig. 2a, b; P < 0.001), indicat-
ing an upregulation of lysosomal activity and the fusion of
autophagosomes with lysosomes in the RBM5 overex-
pressed cells. However, 3-MA inhibited LAMP1 expres-
sion significantly in co-treatment group compared to the
RBM5 group (Fig. 2a, b; P < 0.001).
Overall, these data indicated that RBM5 overexpres-
sion could induce autophagic flux in human lung cancer
A549 cells, and this process could be suppressed by the
autophagy inhibitor, 3-MA.
In order to investigate the mechanism that RBM5 in-
duced autophagy, we evaluated the expression levels of
autophagy regulators, Beclin1, NF-κB/p65, and Bcl-2 by
Western blot analysis. Beclin1 plays an important role in
initiating the formation of autophagosomes, NF-κB/p65
is an inducer of autophagy through the activation of
Beclin1 [36], and Bcl-2 is an inhibitor of Beclin1-
dependent autophagy [24]. The results showed that the
expression levels of Beclin1, as well as NF-κB/p65, were
Fig. 2 Overexpression of RBM5 induced cell autophagy-related protein expression. A549 cells were treated with RBM5 overexpression (RBM5 group),
control plasmids (control group), or RBM5 overexpression combined with 3-MA (RBM5+3-MA group). a Western blot analysis of the protein expression
levels of LC3-I, LC3-II, LAMP1, and β-actin in A549 cells. b Quantification of protein expression relative to β-actin. c Quantification of LC3-II expression
relative to LC3-I. d Western blot analysis of the protein expression levels of NF-κB/p65, Bcl-2, Beclin1, and β-actin in A549 cells. e Quantification of
protein expression relative to β-actin. Data shown are representative of three independent experiments and presented as mean ± SD. *P < 0.05,
**P < 0.01, ***P < 0.001
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increased significantly (P < 0.001) in RBM5 overexpres-
sion group, which were inhibited by co-treatment of
RBM5 and 3-MA (Fig. 2d, e). On the contrary, the ex-
pression level of Bcl-2 was decreased significantly in
RBM5 overexpression group compared to the control
group (Fig. 2d, e; P < 0.001) and can be reversed by 3-MA
in the co-treatment group (Fig. 2d, e; P < 0.01). These data
suggested that overexpression of RBM5 could induce au-
tophagy through the upregulation of Beclin1, which might
consequently switch on the downstream reaction via the
activation of NF-κB/p65,inactivation of Bcl-2, and invoke
the autophagy process.
Pharmacological modulation of autophagy enhanced
overexpressed RBM5-induced apoptosis and
chemosensitivity
To determine whether autophagy induced by RBM5
overexpression played a cytoprotective or cytotoxic role
in A549 cells, we applied autophagy inhibitor 3-MA to
suppress autophagy and examined cell viability by MTT
assay. Our previous studies showed that RBM5 overex-
pression inhibited the growth of both A549 and A549/
DDP cells and sensitized both cells to cisplatin [19, 20].
Similarly, RBM5 overexpressed A549 cells showed a sig-
nificantly lower survival rate (Fig. 3a) and increased sen-
sitivity to cisplatin-induced growth inhibition (Fig. 3b)
compared to control group. While treated with 3-MA
alone had a slightly decrease but not a significant effect
on cellular proliferation, co-treatment with 3-MA and
RBM5 transfection significantly decreased cell viability
(Fig. 3a) and increased sensitivity to cisplatin-induced
growth inhibition (Fig. 3b) compared to the cells treated
with RBM5 transfection alone.
Our previous studies showed that RBM5 inhibited the
growth of A549 cells and resensitized A549/DDP cells to
cisplatin through apoptosis [8, 18–20]. In the present
study, we found that inhibition of autophagy, which was
induced by the co-treatment of overexpressed RBM5 and
3-MA, enhanced RBM5 induced A549 cell growth inhib-
ition and sensitivity to cisplatin. The data above suggested
that autophagy activated by RBM5 overexpression func-
tions as a pro-survival factor and prevents cell death trig-
gered by RBM5. And autophagy inhibition by 3-MA could
enhance RBM5-induced apoptosis and chemosensitivity.
RBM5 overexpression induced autophagy in A549
xenografts in BALB/c nude mice
To determine the potential impact of RBM5 overexpres-
sion on lung cancer cells in vivo, A549 xenografts were
treated with control plasmid or GV287-RBM5 plasmid
via attenuated Salmonella. It has been confirmed that
RBM5 overexpression contributed to the retardation of
the tumor growth and cell death in A549 xenografts in
previous studies [18, 31]. To further validate the autoph-
agy induced by RBM5 overexpression, we assessed the
expression levels of RBM5 and candidate markers of au-
tophagy, LC3, LAMP1, and Beclin1, by immunohisto-
chemistry staining in the tissue from the tumor
xenografts in our in vivo studies following treatment
with attenuated Salmonella carrying control plasmids or
GV287-RBM5 plasmids. First, overexpression of RBM5
was confirmed by immunohistochemistry staining. As
shown in Fig. 4, RBM5 expression was significantly
higher in RBM5 group compared to the control group,
suggesting that the RBM5 was efficiently delivered into
tumor xenografts and overexpressed by attenuated
Salmonella in vivo. In agreement with above cell culture
findings, RBM5 overexpression in tumor xenografts in-
duced LC-3 and LAMP1 localization, indicating that
RBM5 induced autophagic flux in vivo. Moreover,
Beclin1 expression was significantly higher in RBM5
group compared to the control group, suggesting that
the RBM5 induced autophagy through activation of
Beclin1.
Fig. 3 Pharmacological modulation of autophagy enhances overexpressed RBM5-induced apoptosis. A549 cells were treated with RBM5 overexpression
(RBM5 group), control plasmids (control group), RBM5 overexpression combined with 3-MA (RBM5 + 3-MA group), or 3-MA alone (3-MA group). a Cell
viability was examined by MTT assay. b Transfected A549 cells were treated with varying concentrations of cisplatin for 24 h. Cell viability was determined
by MTT assay. Data were presented as mean ± SD for three replicate experiments. **P< 0.01, ***P< 0.001
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Discussion
Previous studies demonstrated that RBM5 displayed ef-
fective antiproliferative activity in cell lines derived from
human solid tumors, such as lung cancer and prostate
cancer, including multidrug resistant cells [8, 18–20].
RBM5 is known as a tumor suppressor gene that has
been shown to function on cell growth inhibition by in-
ducing apoptosis. Autophagy and apoptosis are closely
related programmed cell activities, which are of great
importance to determine cell death and/or survival.
Autophagy is emerging as a key process modulating
tumorigenesis, tumor-stroma interactions and cancer
therapy, but plays a dual, context-dependent role in
tumor suppression and survival [37]. Autophagy plays
a protective role in cancer cells in certain circum-
stances [38]; however, in other circumstances it is in-
volved in type II programmed cell death [39, 40]. From
a therapeutic perspective, understanding when and how
autophagy can be harnessed to kill cancer cells remains
challenging [41]. Therefore, a better understanding about
regulation relationship of RBM5 on autophagy and the
role autophagy plays in cell survival is critical for develop-
ing therapeutic strategies targeting RBM5 in lung cancer
and understanding more about mechanisms of autophagy
regulation.
In the present study, we experimentally conducted over-
expression of RBM5 in human lung adenocarcinoma
A549 cells and for the first time demonstrated that au-
tophagy, aside from apoptosis alone, was also activated by
RBM5 overexpression. The increased autophagic flux in
the RBM5 overexpressed A549 cells was demonstrated by
the enhancement of LC3-II, LC3-II/LC3-I, and Beclin1 to-
gether with the accumulation of AVOs assessed by AO
staining, MDC staining and TEM, and the upregulation of
Fig. 4 Immunohistochemistry assessment of RBM5 and candidate markers of autophagy in A549 xenograft. A549 xenografts were established and
treated with attenuated Salmonella carrying control plasmids (control group) or GV287-RBM5 plasmids (RBM5 group). The mice were sacrificed on
day 42 and the tumors were removed. Expression levels of RBM5 and candidate markers of autophagy, LC3, LAMP1, and Beclin1, were assessed
by immunohistochemistry staining
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lysosomal activity and autophagolysosomal fusion charac-
terized by increased levels of LAMP1. In order to confirm
our in vitro results, the lung adenocarcinoma transplant-
ation in vivo model was made by injecting A549 cells onto
the back of immunocompromised mice and RBM5 gene
was delivered into xenografts by attenuated Salmonella.
As shown in the results, increased autophagic flux in the
RBM5 overexpressed A549 xenografts was confirmed by
the overexpression of LC3, Beclin1, and LAMP1 evaluated
by immunohistochemistry staining.
Autophagy induction in mammalian cells is mainly
dependent upon the activation of the class III PI3K or
PI3K/AKT/mTOR pathways [42]. Beclin1 (Atg6) is a well-
known key regulator of autophagy [43], which governs the
autophagic process by regulating class III PI3K pathway ac-
tivated autophagosome formation [44, 45]. Increased
Beclin1 expression was also observed in the RBM5 overex-
pressed A549 cells and A549 xenografts in the present
study. However, when Beclin1-PI3K III complex was inhib-
ited by 3-MA, Beclin1 expression was downregulated and
autophagic flux was decreased, confirming a crucial role for
Beclin1 in RBM5-induced autophagy in lung cancer cells.
Bcl-2, an anti-apoptotic protein, is also a Beclin1 bind-
ing protein and act as an autophagy regulator [22–24].
As demonstrated in previous studies [18, 19], we found
that RBM5 overexpression decreased the level of bcl-2
protein that occurred, along with the induction of au-
tophagy in A549 cells in the present study, indicating
that downregulation of Bcl-2 was also involved in
RBM5-induced autophagy. Interestingly, we also found
that administration of 3-MA prevented RBM5-induced
downregulation of Bcl-2. Likewise, results were reported
by Xie H et al. that Beclin1 proteins was decreased but
Bcl-2 was upregulated in 3-MA-treated H9c2 rat cardio-
myocytes [46], which might be due to strong interaction
between Beclin1 and Bcl-2.
NF-κB/p65 is another regulator of Beclin1-mediated
autophagy [36, 47], which could be inhibited by 3-MA
[48]. Our results again showed that overexpression of
RBM5 activated Beclin1-mediated autophagy mainly
through activation of NF-κB/p65 pathway and inhibition
of Bcl-2. NF-κB/p65 protein levels, along with cell au-
tophagy were overexpressed by RBM5 overexpression,
which was inhibited by 3-MA in A549 cells, indicating
that NF-κB/p65 was regulated by RBM5 and was in-
volved in RBM5-induced autophagy.
However, the mechanisms that RBM5 regulates
Beclin-1, Bcl-2, and NF-κB/p65 still need to be investi-
gated. It is reported that RBM5 is a component of pre-
spliceosomal complexes that regulates the alternative
splicing of several mRNAs, such as Fas and caspase-2
[49, 50]. As overexpression of Beclin1 and NF-κB/p65
and downregulation of Bcl-2 can be inhibited by 3-MA,
RBM5 may directly or indirectly regulate those genes
expression through regulating such genes expression of
class III PI3K pathway, like Beclin1 or other genes, by al-
ternative splicing of mRNAs.
Besides those genes examined in this study, our previ-
ous studies revealed that RBM5 also regulates such
genes expression as Bcl-2 family [18, 19], EGFR [4, 31],
and β-catenin [51], which are all important autophagy
regulators [23, 24, 52–55]. Thus, it is a complicated
process of autophagy regulation by RBM5 that needs to
be further investigated.
The role of autophagy in carcinogenesis is a paradox,
which can be a pro-survival mechanism to deteriorate
therapeutic outcomes or act as programmed cell death
to improve overall anti-tumor efficacy [56]. In order to
investigate the role of activated autophagy plays in
RBM5-induced cell death, the present study used a spe-
cific autophagy inhibitor, 3-MA, which is a class III
phosphatidylinositol 3-kinase (PI3K) inhibitor. RBM5
overexpression induced autophagy in A549 cells was sig-
nificantly inhibited by the administration of 3-MA. Fur-
thermore, the inhibition of autophagy enhanced RBM5-
induced cell death and increased cancer cell sensitivity to
cisplatin in A549 cells, maybe through enhanced apoptosis.
These findings indicate that autophagy may be utilized as a
protective mechanism against cell death in RBM5 overex-
pressed A549 cells and that its inhibition may improve the
anti-tumor efficacy of RBM5 in lung cancer therapies.
Apoptosis is a natural way of removing aged cells
from the body and is the way by which most of the anti-
cancer therapies eliminate malignant cells. However,
several pathways modulate the apoptosis signaling and
contribute to apoptosis resistance in cancers, such as
Bcl-2 and Mcl-1 proteins, autophagy processes, aberrant
nuclear export signaling, etc [57]. Autophagy has been
observed to protect cancer cells from apoptosis upon
certain anti-cancer drugs [58, 59] and gene targeting
therapies [60, 61]. Our previous studies demonstrated
that RBM5 can inhibit the growth of lung cancer cells
and enhance cancer cells’ sensitivity to cisplatin through
apoptosis [8, 18–20]. In the present study, we found that
autophagy induced by RBM5 overexpression in lung
cancer cells acted a pro-survival way. However, actually
RBM5 overexpression caused cell growth inhibition, in-
dicating that in the lung cancer cells, RBM5-induced
apoptosis overweighs RBM5-induced autophagy and in-
duces apoptotic cell death. Co-treatment with 3-MA
inhibited RBM5-induced autophagy, enhanced RBM5-
induced apoptosis and chemosensitivity. Thus, modulat-
ing the sensitivity and regulatory mechanism of cells to
RBM5 overexpression, such as through the use of 3-
MA, could potentially serve as a strategy in sensitizing
and reducing resistance of lung cancer cells to RBM5
targeting therapy by blocking RBM5-mediated protect-
ive autophagy.
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Conclusions
Overall, our data revealed that the pro-survival autophagy
is enhanced by ectopic RBM5 overexpression, and inhib-
ition of autophagy can enhance RBM5-induced apoptosis
and increase cancer cells sensitivity to cisplatin. Our study
suggests that a combination of RBM5 overexpression and
autophagic inhibitor could be a good approach to treat
NSCLC and resensitize cells to anti-tumor drugs.
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